Investor Update

Basel, 14 June 2013

Anti-Cancer Agent Tarceva, Obtained Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations in Japan

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.